Revascularization Risk in Symptomatic Versus Asymptomatic Patients – Relative Versus Absolute Risk: The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) (S22.001)

BACKGROUND: Carotid revascularization was addressed by NASCET and ACAS. NASCET showed a 2-year stroke and death of 32.3% in medical patients and a 15.8% incidence in surgical patients (16.5% absolute/51% relative reduction). Similarly, ACAS revealed an 11% 5-year risk in medical patients and 5.1% in surgical patients (5.9% absolute reduction/53% relative reduction). Absolute risk (rather than relative risk) reduction is of prime interest to the patient. However, in these studies, treatment efficacy was assessed on a relative basis, and these procedures were equally efficacious (51% vs. 53% relative risk). The higher event rates in the symptomatic patients resulted in a larger absolute risk reduction in NASCET (16.5% vs. 5.9%). CREST is the only carotid revascularization study to include both symptomatic and asymptomatic patients undergoing CEA or carotid artery stenting (CAS), and we looked at absolute and relative risks associated with both procedures. DESIGN/METHODS: Treatment differences in CREST by symptomatic status were reviewed and interaction terms analyzed. RESULTS: Symptomatic periprocedural stroke and death rates were 6% for CAS vs. 3.2% for CEA (2.8% absolute/47% relative difference/p = 0.02), and were 2.5% for CAS vs. 1.4% for CEA (1.2% absolute/53% relative difference/p = 0.15) for asymptomatic. While treatment differences in periprocedural rates were significant for symptomatic but not asymptomatic patients, there was no difference in treatment efficacy as determined by relative risk reduction. Even the most prominent interaction terms were clearly not significant, p > 0.38. CONCLUSIONS: There is no evidence of a CAS-CEA difference in treatment efficacy by symptomatic status in CREST. There are significant findings in symptomatic patients. This is likely a product of an increased background rate of events in this strata. While symptomatic status can identify a subgroup with an increased background rate, other factors (e.g. age or stenosis) could identify subgroups of asymptomatic patients with high event rates and large absolute treatment differences. Disclosure: Dr. Voeks has nothing to disclose. Dr. Hye has received research support from Abbott. Dr. Brown has nothing to disclose. Dr. Meschia has nothing to disclose. Dr. Lal has nothing to disclose. Dr. Sheffet has nothing to disclose. Dr. Howard has nothing to disclose. Dr. Howard has received personal compensation for activities with Bayer Healthcare and Abbott. Dr. Howard has received research support from Amgen and Bayer. Dr. Brott has received personal compensation for activities with 3D Communications and Edwards Lifesciences, LLC.